Ambulatory Blood Pressure Monitoring in Rivaroxaban Therapy

King's College Hospital NHS Trust

Status

Withdrawn

Conditions

Hypotension

Treatments

Device: Ambulatory blood pressure monitoring

Study type

Interventional

Funder types

Other

Identifiers

NCT02539953

KCH1002

Details and patient eligibility

About

One in ten patients on rivaroxaban therapy have dizziness and reductions in blood pressure. The investigators intend to monitor the ambulatory blood pressure of such patients in order to assess whether this is a true haemodynamic effect.

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Aged 18-75 years
Able to provide written, informed consent
Taking rivaroxaban for any indication within the license of the drug, both once daily and twice daily dosing can be included
Have measurable rivaroxaban levels on at least one occasion (this will be in line with standard of care, there will be no extra blood samples for the study)
Not taking concomitant medication that can affect rivaroxaban metabolism (including amiodarone, dronedarone, -azole antifungals, protease inhibitors)
On no antihypertensive or vasoactive medication
Have a baseline BP recording taken in clinic

Exclusion criteria

Unable to provide written, informed consent
Presence of concomitant medication that may alter rivaroxaban levels and confound results (see above)
Unwilling to undergo ambulatory blood pressure monitoring
Contraindication to ambulatory blood pressure monitoring